Bone Biologics Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $1.1M | $2.1M | $6.9M | $1.6M | $82,044 |
| Operating expenses | $3.2M | $4.2M | $9.4M | $3.7M | $1.1M |
| Operating income | -$3.2M | -$4.2M | -$9.4M | -$3.7M | -$1.1M |
| Pretax income | — | — | — | — | -$1.6M |
| Income tax expense | — | — | — | — | $1,600 |
| Net income | -$3.1M | -$4.1M | -$8.9M | -$1.5M | -$1.6M |
| Balance Sheet | |||||
| Cash and equivalents | — | — | — | — | $6.7M |
| Current assets | $5.8M | $3.9M | $3.7M | $8.5M | — |
| Total assets | $5.8M | $3.9M | $3.7M | $8.5M | $6.7M |
| Current liabilities | $418,587 | $377,712 | $831,402 | $2.5M | $99,909 |
| Total liabilities | $418,587 | $377,712 | $831,402 | $2.5M | $99,909 |
| Stockholders' equity | $5.4M | $3.5M | $2.9M | $5.9M | $6.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$2.7M | -$4.1M | -$9.6M | -$3.6M | -$1.2M |
| Stock-based compensation | $256,358 | $188,819 | $152,599 | $266,633 | $207,035 |
Shares outstanding 1.8M · Free float 94.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.